

Special Issue

Treatment Options and Therapeutics for Non-small Cell Lung Cancer

Message from the Guest Editor

The treatment of non-small cell lung cancer (NSCLC) has heralded an era of precision medicine based on the detection of mutated driver kinases and the development of specific inhibitors targeting altered EGFR receptors, rearranged anaplastic lymphoma kinase (ALK), ROS1, MET, and a host of other minor oncogenic proteins. Knowledge of the 3D structure of the mutated kinases allowed for rational drug design fitting therapeutics mostly to the ATP binding pocket of the enzymes. Clinical administration of these tyrosine kinase inhibitors (TKIs) results in prolonged survival of up to several years of the subpopulation of patients expressing suitable molecular markers. However, drug resistance invariably develops and the affected patients have to be treated with new drugs targeting secondary mutations or bypass pathways. Accordingly, for mutated EGFR and rearranged ALK, several TKIs are approved and can be applied in sequence and a host of new compounds are in preclinical testing and early trials.

Guest Editor

Prof. Gerhard Hamilton
Medizinische Universität Wien, Vienna, Austria

Deadline for manuscript submissions

closed (30 September 2020)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/43054

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)